Bayer Nisocor commercialization decision pending; Adalat CC jumped to $120 mil. U.S. sales in 1994.
Executive Summary
NISOLDIPINE U.S. COMMERCIALIZATION DECISION PENDING AT BAYER three months after FDA's Feb. 2 approval for the extended-release calcium channel blocker. The Bayer Pharmaceutical Division (previously Miles) says it is continuing to evaluate options for nisoldipine, which currently carries the brandname Nisocor, including outlicensing and comarketing. Nisoldipine extended-release is marketed in many countries outside the U.S.